{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:35:10Z","timestamp":1788813310466,"version":"build-2803163510"},"reference-count":59,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1124\/jpet.123.001679","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T15:50:27Z","timestamp":1697817027000},"page":"81-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Pramlintide an Adjunct to Insulin Therapy: Challenges and Recent Progress in Delivery"],"prefix":"10.1016","volume":"388","author":[{"given":"Sai Pradyuth","family":"Kommera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankur","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Chitkara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupama","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1124\/jpet.123.001679_bib1","first-page":"S4","article-title":"Standards of medical care in diabetes--2007","volume":"30","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1124\/jpet.123.001679_bib2","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1111\/dom.14972","article-title":"A co-formulation of pramlintide and insulin A21G (ADO09) improves postprandial glucose and short-term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes","volume":"25","author":"Andersen","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/jpet.123.001679_bib3","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/dom.14302","article-title":"ADO09, a co-formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes","volume":"23","author":"Andersen","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/jpet.123.001679_bib4","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1021\/acs.molpharmaceut.7b01009","article-title":"Inhibition of human amylin aggregation and cellular toxicity by lipoic acid and ascorbic acid","volume":"15","author":"Azzam","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1124\/jpet.123.001679_bib5","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1074\/jbc.M111.327817","article-title":"Fibril structure of human islet amyloid polypeptide","volume":"287","author":"Bedrood","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.123.001679_bib6","doi-asserted-by":"crossref","first-page":"e689","DOI":"10.1016\/S2589-7500(21)00218-1","article-title":"Fully closed-loop insulin delivery-are we nearly there yet?","volume":"3","author":"Boughton","year":"2021","journal-title":"Lancet Digit Health"},{"key":"10.1124\/jpet.123.001679_bib7","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1111\/bph.13496","article-title":"Amylin structure-function relationships and receptor pharmacology: implications for amylin mimetic drug development","volume":"173","author":"Bower","year":"2016","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.123.001679_bib8","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3109\/08982104.2015.1076462","article-title":"Molecular confinement of human amylin in lipidic nanoparticles","volume":"26","author":"Braga","year":"2016","journal-title":"J Liposome Res"},{"key":"10.1124\/jpet.123.001679_bib9","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1021\/la902980d","article-title":"Inhibition of IAPP and IAPP(20-29) fibrillation by polymeric nanoparticles","volume":"26","author":"Cabaleiro-Lago","year":"2010","journal-title":"Langmuir"},{"key":"10.1124\/jpet.123.001679_bib10","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1345\/aph.1M210","article-title":"The role of pramlintide for weight loss","volume":"44","author":"Dunican","year":"2010","journal-title":"Ann Pharmacother"},{"key":"10.1124\/jpet.123.001679_bib11","doi-asserted-by":"crossref","first-page":"18820","DOI":"10.1074\/jbc.M111.331181","article-title":"Amyloid \u03b2 (A\u03b2) peptide directly activates amylin-3 receptor subtype by triggering multiple intracellular signaling pathways","volume":"287","author":"Fu","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.123.001679_bib12","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1007\/s11095-017-2233-0","article-title":"Rapid-acting and human insulins: hexamer dissociation kinetics upon dilution of the pharmaceutical formulation","volume":"34","author":"Gast","year":"2017","journal-title":"Pharm Res"},{"key":"10.1124\/jpet.123.001679_bib13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1006\/jsbi.1997.3858","article-title":"Polymorphic fibrillar assembly of human amylin","volume":"119","author":"Goldsbury","year":"1997","journal-title":"J Struct Biol"},{"key":"10.1124\/jpet.123.001679_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2019.107414","article-title":"Rapid gastric emptying in diabetes mellitus: pathophysiology and clinical importance","volume":"33","author":"Goyal","year":"2019","journal-title":"J Diabetes Complications"},{"key":"10.1124\/jpet.123.001679_bib15","doi-asserted-by":"crossref","first-page":"12206","DOI":"10.1074\/jbc.M312452200","article-title":"Human amylin oligomer growth and fibril elongation define two distinct phases in amyloid formation","volume":"279","author":"Green","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.123.001679_bib16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.colsurfb.2012.01.021","article-title":"Polymeric particles for the controlled release of human amylin","volume":"94","author":"Guerreiro","year":"2012","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"Suppl 1","key":"10.1124\/jpet.123.001679_bib17","first-page":"A118","article-title":"In an open-label clinical study pramlintide lowered A1C, body weight, and insulin use in patients with type 1 diabetes failing to achieve glycemic targets with insulin therapy","volume":"54","author":"Guthrie","year":"2005","journal-title":"Diabetes"},{"key":"10.1124\/jpet.123.001679_bib18","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1124\/pr.115.010629","article-title":"Amylin: pharmacology, physiology, and clinical potential","volume":"67","author":"Hay","year":"2015","journal-title":"Pharmacol Rev"},{"key":"10.1124\/jpet.123.001679_bib19","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1021\/acs.molpharmaceut.6b00678","article-title":"Self-assembly PEGylation retaining activity (SPRA) technology via a host-guest interaction surpassing conventional PEGylation methods of proteins","volume":"14","author":"Hirotsu","year":"2017","journal-title":"Mol Pharm"},{"key":"10.1124\/jpet.123.001679_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134091","article-title":"Secondary structure of rat and human amylin across force fields","volume":"10","author":"Hoffmann","year":"2015","journal-title":"PLoS One"},{"key":"10.1124\/jpet.123.001679_bib21","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1007\/s11095-006-9098-y","article-title":"Chemical and thermal stability of insulin: effects of zinc and ligand binding to the insulin zinc-hexamer","volume":"23","author":"Huus","year":"2006","journal-title":"Pharm Res"},{"issue":"Suppl 1","key":"10.1124\/jpet.123.001679_bib22","first-page":"A12","article-title":"In an open-label clinical study pramlintide lowered A1c, body weight, and insulin use in patients with type 2 diabetes failing to achieve glycemic targets","volume":"54","author":"Karl","year":"2005","journal-title":"Diabetes"},{"key":"10.1124\/jpet.123.001679_bib23","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1039\/C9SM02463H","article-title":"Fractal self-assembly and aggregation of human amylin","volume":"16","author":"Khatun","year":"2020","journal-title":"Soft Matter"},{"key":"10.1124\/jpet.123.001679_bib24","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/j.bbamem.2010.05.022","article-title":"The N-terminal fragment of human islet amyloid polypeptide is non-fibrillogenic in the presence of membranes and does not cause leakage of bilayers of physiologically relevant lipid composition","volume":"1798","author":"Khemt\u00e9mourian","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/jpet.123.001679_bib25","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1111\/j.1742-4658.2006.05367.x","article-title":"The aggregation potential of human amylin determines its cytotoxicity towards islet beta-cells","volume":"273","author":"Konarkowska","year":"2006","journal-title":"FEBS J"},{"key":"10.1124\/jpet.123.001679_bib26","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/014572179902500310","article-title":"Clinical implications of amylin and amylin deficiency","volume":"25","author":"Kruger","year":"1999","journal-title":"Diabetes Educ"},{"key":"10.1124\/jpet.123.001679_bib27","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/nyas.13376","article-title":"Cucurbit[7]uril: an emerging candidate for pharmaceutical excipients","volume":"1398","author":"Kuok","year":"2017","journal-title":"Ann N Y Acad Sci"},{"key":"10.1124\/jpet.123.001679_bib28","doi-asserted-by":"crossref","first-page":"626","DOI":"10.4239\/wjd.v6.i4.626","article-title":"Insulin action in muscle and adipose tissue in type 2 diabetes: The significance of blood flow","volume":"6","author":"Lambadiari","year":"2015","journal-title":"World J Diabetes"},{"key":"10.1124\/jpet.123.001679_bib29","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.regpep.2009.12.008","article-title":"Oral delivery of mouse [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, in male Swiss Webster mice: a study comparing the pharmacokinetics of oral delivery to intraperitoneal, subcutaneous, intramuscular, and intranasal administration","volume":"160","author":"Lee","year":"2010","journal-title":"Regul Pept"},{"key":"10.1124\/jpet.123.001679_bib30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.regpep.2012.08.006","article-title":"[D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, augments the effects of orally delivered exenatide and pramlintide acetate on energy balance and glycemic control in insulin-resistant male C57BLK\/6-m db\/db mice","volume":"179","author":"Leinung","year":"2012","journal-title":"Regul Pept"},{"key":"10.1124\/jpet.123.001679_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/diacare.26.1.1","article-title":"Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps","volume":"26","author":"Levetan","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1124\/jpet.123.001679_bib32","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/dmrr.419","article-title":"Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study","volume":"20","author":"Maggs","year":"2004","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1124\/jpet.123.001679_bib33","article-title":"Ultra-fast insulin-pramlintide co-formulation for improved glucose management in diabetic rats","volume":"8","author":"Maikawa","year":"2021","journal-title":"Adv Sci (Weinh)"},{"key":"10.1124\/jpet.123.001679_bib34","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1021\/acs.biomac.1c00474","article-title":"Engineering insulin cold chain resilience to improve global access","volume":"22","author":"Maikawa","year":"2021","journal-title":"Biomacromolecules"},{"key":"10.1124\/jpet.123.001679_bib35","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41551-020-0555-4","article-title":"A co-formulation of supramolecularly stabilized insulin and pramlintide enhances mealtime glucagon suppression in diabetic pigs","volume":"4","author":"Maikawa","year":"2020","journal-title":"Nat Biomed Eng"},{"key":"10.1124\/jpet.123.001679_bib36","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrendo.2017.39","article-title":"Insulin analogues in type 1 diabetes mellitus: getting better all the time","volume":"13","author":"Mathieu","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"10.1124\/jpet.123.001679_bib37","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.physbeh.2014.01.013","article-title":"Amylin activates distributed CNS nuclei to control energy balance","volume":"136","author":"Mietlicki-Baase","year":"2014","journal-title":"Physiol Behav"},{"key":"10.1124\/jpet.123.001679_bib38","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.bbamem.2011.06.012","article-title":"Structure and membrane orientation of IAPP in its natively amidated form at physiological pH in a membrane environment","volume":"1808","author":"Nanga","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/jpet.123.001679_bib39","doi-asserted-by":"crossref","first-page":"8252","DOI":"10.1021\/ja9010095","article-title":"Three-dimensional structure and orientation of rat islet amyloid polypeptide protein in a membrane environment by solution NMR spectroscopy","volume":"131","author":"Nanga","year":"2009","journal-title":"J Am Chem Soc"},{"key":"10.1124\/jpet.123.001679_bib40","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0026-0495(99)90232-9","article-title":"The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus","volume":"48","author":"Nyholm","year":"1999","journal-title":"Metabolism"},{"key":"10.1124\/jpet.123.001679_bib41","doi-asserted-by":"crossref","first-page":"11982","DOI":"10.1074\/jbc.M809085200","article-title":"Dynamic \u03b1-helix structure of micelle-bound human amylin","volume":"284","author":"Patil","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.123.001679_bib42","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/826706","article-title":"Amylin uncovered: a review on the polypeptide responsible for type II diabetes","volume":"2013","author":"Pillay","year":"2013","journal-title":"BioMed Res Int"},{"key":"10.1124\/jpet.123.001679_bib43","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2147\/vhrm.2006.2.3.203","article-title":"Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes","volume":"2","author":"Pullman","year":"2006","journal-title":"Vasc Health Risk Manag"},{"key":"10.1124\/jpet.123.001679_bib44","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/15209150252924094","article-title":"Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes","volume":"4","author":"Ratner","year":"2002","journal-title":"Diabetes Technol Ther"},{"key":"10.1124\/jpet.123.001679_bib45","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ecl.2004.03.002","article-title":"The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals","volume":"33","author":"Reaven","year":"2004","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1124\/jpet.123.001679_bib46","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13098-021-00770-0","article-title":"Long-term glycemic variability and risk of stroke in patients with diabetes: a meta-analysis","volume":"14","author":"Ren","year":"2022","journal-title":"Diabetol Metab Syndr"},{"key":"10.1124\/jpet.123.001679_bib47","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/dom.12504","article-title":"Fixed ratio dosing of pramlintide with regular insulin before a standard meal in patients with type 1 diabetes","volume":"17","author":"Riddle","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/jpet.123.001679_bib48","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.addr.2021.04.003","article-title":"Lipid based nanocarriers for effective drug delivery and treatment of diabetes associated liver fibrosis","volume":"173","author":"Salunkhe","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1124\/jpet.123.001679_bib49","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1006\/jmbi.2000.3908","article-title":"The protofilament substructure of amyloid fibrils","volume":"300","author":"Serpell","year":"2000","journal-title":"J Mol Biol"},{"key":"10.1124\/jpet.123.001679_bib50","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1080\/10837450.2019.1621896","article-title":"Physico-chemical stability of co-formulation of PEGylated human amylin with insulin","volume":"24","author":"Sin\u00e9sia","year":"2019","journal-title":"Pharm Dev Technol"},{"key":"10.1124\/jpet.123.001679_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138803","article-title":"Monoconjugation of human amylin with methylpolyethyleneglycol","volume":"10","author":"Sisnande","year":"2015","journal-title":"PLoS One"},{"issue":"Suppl 2","key":"10.1124\/jpet.123.001679_bib52","doi-asserted-by":"crossref","first-page":"S253","DOI":"10.2337\/dc09-S318","article-title":"Insulin therapy for type 2 diabetes","volume":"32","author":"Swinnen","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1124\/jpet.123.001679_bib53","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3390\/pharmaceutics14030553","article-title":"Injectable biodegradable silica depot: two months of sustained release of the blood glucose lowering peptide, pramlintide","volume":"14","author":"Tyagi","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1124\/jpet.123.001679_bib54","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00063030-200822050-00004","article-title":"The impact of PEGylation on biological therapies","volume":"22","author":"Veronese","year":"2008","journal-title":"BioDrugs"},{"key":"10.1124\/jpet.123.001679_bib55","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.2337\/diacare.26.11.3074","article-title":"Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study","volume":"26","author":"Weyer","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1124\/jpet.123.001679_bib56","doi-asserted-by":"crossref","first-page":"724","DOI":"10.2337\/diacare.25.4.724","article-title":"A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes","volume":"25","author":"Whitehouse","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1124\/jpet.123.001679_bib57","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/ijch.201700092","article-title":"Applications of cucurbiturils (n=7 or 8) in pharmaceutical sciences and complexation of biomolecules","volume":"58","author":"Yin","year":"2018","journal-title":"Isr J Chem"},{"key":"10.1124\/jpet.123.001679_bib58","doi-asserted-by":"crossref","first-page":"9900","DOI":"10.1021\/bi800828u","article-title":"Amylin proprotein processing generates progressively more amyloidogenic peptides that initially sample the helical state","volume":"47","author":"Yonemoto","year":"2008","journal-title":"Biochemistry"},{"key":"10.1124\/jpet.123.001679_bib59","first-page":"1642","article-title":"Dextran sulfate\/pramlintide polyelectrolyte nanoparticles as a promising delivery system: optimization, evaluation of supramolecular interactions and effect on conformational stability of the peptide drug","volume":"32","author":"Zuglianello","year":"2021","journal-title":"J Braz Chem Soc"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524171406?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524171406?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.123.001679","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:32:50Z","timestamp":1739971970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524171406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0022356524171406"],"URL":"https:\/\/doi.org\/10.1124\/jpet.123.001679","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pramlintide an Adjunct to Insulin Therapy: Challenges and Recent Progress in Delivery","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.123.001679","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}